Literature DB >> 22752423

Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.

Rodolfo Sacco1,2, Lorenzo Faggioni3, Irene Bargellini3, Antonio Romano4, Marco Bertini4, Barbara Ginanni3, Valentina Battaglia3, Michele Bertoni4, Elena Bozzi3, Graziana Federici4, Salvatore Metrangolo4, Giuseppe Parisi4, Emanuele Neri3, Elisabetta Sodini4, Emanuele Tumino4, Giampaolo Bresci4, Carlo Bartolozzi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22752423     DOI： 10.1007/s12029-012-9403-4

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  20 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

3.  Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.

Authors:  Rodolfo Sacco; Irene Bargellini; Barbara Ginanni; Marco Bertini; Elena Bozzi; Emanuele Altomare; Valentina Battaglia; Antonio Romano; Emanuele Tumino; Matteo Di Biase; Giampaolo Bresci; Carlo Bartolozzi
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 4.  Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  S Jelic
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

5.  Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon.

Authors:  Chaan S Ng; Xiaohong Wang; Silvana C Faria; E Lin; Chusilp Charnsangavej; Nizar M Tannir
Journal:  AJR Am J Roentgenol       Date:  2010-01       Impact factor: 3.959

Review 6.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 7.  Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.

Authors:  Elizabeth Manchen; Caroline Robert; Camillo Porta
Journal:  J Support Oncol       Date:  2011 Jan-Feb

Review 8.  HCC and angiogenesis: possible targets and future directions.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

9.  Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience.

Authors:  Dushyant V Sahani; Nagaraj-Setty Holalkere; Peter R Mueller; Andrew X Zhu
Journal:  Radiology       Date:  2007-06       Impact factor: 11.105

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.